Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23157471 | 0.98 | TLR2 (0.38) | TSHRCYP1A2ALDH1A1MAPTTHRB | |
| SCHEMBL22489508 | 0.98 | TLR2 (0.38) | TSHRCYP1A2ALDH1A1MAPTTHRB | |
| SCHEMBL19519866 | 0.98 | TLR2 (0.38) | TSHRCYP1A2ALDH1A1MAPTTHRB | |
| Ethylenediamine SCHEMBL7702384 | 0.86 | TSHR (0.43) | TSHRCYP1A2ALDH1A1MAPTTHRB | |
| SCHEMBL4859360 | 0.84 | TSHR (0.42) | TSHRALDH1A1MAPTPOLBGAA | |
| SCHEMBL27386816 | 0.84 | TDP1 (0.42) | TSHRALDH1A1TLR2POLBGAA | |
| SCHEMBL28294539 | 0.83 | TDP1 (0.45) | TSHRCYP1A2ALDH1A1MAPTTHRB | |
| SCHEMBL20210489 | 0.83 | MAPT (0.44) | TSHRALDH1A1MAPTPOLBGAA | |
| SCHEMBL18704286 | 0.83 | TDP1 (0.45) | TSHRALDH1A1MAPTPOLBGAA | |
| SCHEMBL9493736 | 0.82 | TSHR (0.44) | TSHRCYP1A2ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397672-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | FUJIFILM Corporation (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | PFIZER INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | TSHR 645/4885CYP1A2 4379/4885ALDH1A1 3319/4885 |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | TSHR 3308/4885CYP1A2 4860/4885ALDH1A1 3065/4885 |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | TSHR 3787/4885CYP1A2 4784/4885ALDH1A1 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.